P Duquette
Overview
Explore the profile of P Duquette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spelman T, Herring W, Acosta C, Hyde R, Jokubaitis V, Pucci E, et al.
J Med Econ
. 2023 Dec;
27(1):109-125.
PMID: 38085684
Aim: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis...
2.
Lefort M, Sharmin S, Andersen J, Vukusic S, Casey R, Debouverie M, et al.
BMC Med Res Methodol
. 2022 May;
22(1):155.
PMID: 35637426
Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment...
3.
Freedman M, Duquette P, GrandMaison F, Lee L, Vorobeychik G, Lara N, et al.
Curr Med Res Opin
. 2019 Jan;
35(5):767-776.
PMID: 30614288
Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who...
4.
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, et al.
Eur J Neurol
. 2018 Oct;
26(2):363-370.
PMID: 30298572
Background And Purpose: Treatment options in primary progressive multiple sclerosis (PPMS) are scarce and, with the exception of ocrelizumab, anti-inflammatory agents have failed to show efficacy in ameliorating disability progression....
5.
Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, et al.
Eur J Neurol
. 2016 Jan;
23(4):729-36.
PMID: 26782663
Background And Purpose: Early relapse outcomes in long-term stable patients switching from interferon β/glatiramer acetate (IFNβ/GA) to oral therapy are unknown. Objective: The objective of this study was to compare...
6.
Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, GrandMaison F, et al.
Eur J Neurol
. 2015 Mar;
22(6):981-9.
PMID: 25808578
Background And Purpose: Early prediction of long-term disease evolution is a major challenge in the management of multiple sclerosis (MS). Our aim was to predict the natural course of MS...
7.
Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato M, et al.
Acta Neurol Scand
. 2012 Sep;
127(5):301-8.
PMID: 22970985
Background: Patients with multiple sclerosis (MS) are more frequently born in spring when compared to autumn. Fluctuation of UV-light has been hypothesized to drive this phenomenon. Aim: To assess the...
8.
Lechner-Scott J, Spencer B, DE Malmanche T, Attia J, Fitzgerald M, Trojano M, et al.
Mult Scler
. 2011 Dec;
18(7):974-82.
PMID: 22185806
Background: With the advent of MRI scanning, the value of lumbar puncture to assess oligoclonal band (OCB) status-for the diagnosis of multiple sclerosis (MS) is increasingly uncertain. One major issue...
9.
Demers M, Rouleau I, Scherzer P, Ouellet J, Jobin C, Duquette P
Can J Neurol Sci
. 2011 Aug;
38(5):728-33.
PMID: 21856576
Objective: Despite the evidence of cognitive deficits in Multiple Sclerosis (MS) patients, evaluation of their cognitive integrity is often limited to the use of clinical interviews and questionnaires. However, the...
10.
Metz L, Li D, Traboulsee A, Myles M, Duquette P, Godin J, et al.
Mult Scler
. 2009 Sep;
15(10):1183-94.
PMID: 19776092
Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate in relapsing-remitting multiple sclerosis. The effect of minocycline plus glatiramer acetate was evaluated in this double-blind,...